Suzhou Connect Biopharma Starts Phase I Trial of Autoimmune Drug

Suzhou Connect Biopharmaceuticals will begin a Phase I clinical trial in Australia of CBP-307, a orally active molecule aimed at autoimmune diseases. CBP-30 is a second generation moderator of the S1P1 G-protein coupled receptor (GPCR). S1P1 is a proven drug target for autoimmune diseases such as multiple sclerosis, psoriasis and inflammatory bowel disease. According to Suzhou Connect, CBP-307 demonstrated fewer side effects in preclinical testing than the presently marketed S1P1 agonist. More details.... Share this with colleagues: // //